INM NASDAQ Week ended 31 Jul 2026

Weekly Investor Report

InMed Pharmaceuticals Inc · Healthcare · Drug Manufacturers - Specialty & Generic

Open interactive chart View report data
Latest close 1.47 USD
-14.0% latest week
Weekly setup

Mixed setup

The weekly trend is active. Price is 31.7% above the Trend Line and sits at 46.5% of its 52-week range. The latest completed week returned -14.0%, after a -5.8% four-week move. The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive. The latest news-sentiment score is 55/100. Near-term considerations: volume confirmation is below normal; earnings are due in 52d.

Setup score 38 out of 100
Latest Close 1.47 USD 31 Jul 2026
1W Return -14.0% latest completed week
4W Return -5.8% short-term follow-through
12W Return 126.2% quarterly tape
Trend Breadth 11.5% 6 of 52 weeks active
Volume Ratio 0.1x vs 13-week average
What is working
  • The trend backdrop is active with a 6-week active streak.
  • Price is above the Trend Line, keeping the weekly tape constructive.
  • Activity pressure is positive on the latest completed week.
  • Activity pressure is constructive, supporting the smart-money activity read.
What could go wrong
  • Price is below Fair Value, so the market is still discounting the latest tape.
  • Next-week expectancy is negative at 43.60% based on similar historical setup states.
  • The share remains more than 20% below its 52-week high.
  • The latest week was a sharp negative move.
What to watch next
  • Trend Line remains the key weekly regime level.
  • Activity pressure is the gauge to monitor for confirmation or fade.
  • A volume ratio above 1.5x would show stronger participation in the next move.
Price follow-through -14.0% Latest completed week; four-week move -5.8%. Indicator stack 27/67 Trend and activity pressure are weighted against the latest 12-week confirmation window. Trend backdrop Active The trend backdrop defines the current weekly regime. Patient Capital Quiet Activity-pressure buy-signal status for institutional accumulation timing. Next-Week Expectancy Negative 43.60% Historical one-week expectancy contributes to the evidence score when direction is confirmed. News sentiment 55/100 43 relevant articles in the latest sentiment read. Event risk 52d Next report is scheduled for 23 Sep 2026; event risk rises as the date approaches.
01 · Price action

Where price is—and whether the trend supports it

The weekly trend is active. Price is 31.7% above the Trend Line and sits at 46.5% of its 52-week range. The latest completed week returned -14.0%, after a -5.8% four-week move.

Study the full chart

52-week price path

Price vs Trend Line and Fair Value
Price Trend Line Fair Value
02 · Volume and demand

Is real participation confirming the move?

Latest weekly volume is 0.1x the 13-week average. Participation is below its recent norm, so price strength is not receiving full volume confirmation.

26-week volume confirmation

Bar height shows volume; colour shows the weekly price direction
6 Feb 13 Feb 20 Feb 27 Feb 6 Mar 13 Mar 20 Mar 27 Mar 3 Apr 10 Apr 17 Apr 24 Apr 1 May 8 May 15 May 22 May 29 May 5 Jun 12 Jun 19 Jun 26 Jun 3 Jul 10 Jul 17 Jul 24 Jul 31 Jul
Up week Down week
Demand beneath price

Activity pressure and institutional-style signals

These indicators assess whether participation is improving beneath the headline price move. They are supporting evidence, not proof of institutional buying.

Activity pressure path

Latest 0.7412-week average 0.34

12-week confirmation

Trend active6/12Active trend-backdrop weeks in the latest 12-week window.
Positive pressure12/12Weeks with constructive activity pressure in the latest 12-week window.
Positive leadership1/12Weeks with positive relative leadership in the latest 12-week window.
Activity pressure0.74Current proprietary activity-pressure read.
Buy signals0Accumulation signal count in the latest 12 weeks.
Reversal markers0No reversal markers

No recent accumulation markers. No reversal markers.

03 · Momentum and leadership

Is performance persistent—and is the stock leading?

Performance is -5.8% over four weeks, 126.2% over 12 weeks, and -38.5% over one year. The current trend has remained active for 6 consecutive weeks.

Performance by holding period

1W-14.0%
4W-5.8%
12W126.2%
26W33.6%
52W-38.5%
Active trend streak6 weeks
Active weeks in one year6
Trend breadth11.5%

Activity pressure vs relative leadership

Activity pressureRelative leadership
Pressure0.98Latest activity-pressure read.
Pressure change-11.1%Four-week change in activity pressure.
Leadership-6.13Latest relative-leadership reading.
RS change44.7%Four-week change in relative leadership.
04 · Fundamentals and valuation

What investors are paying for—and the quality behind it

The latest factor snapshot indicates quality is middle-of-the-pack; growth is moderate; valuation is neither clearly cheap nor expensive.

Open full factor analysis
Factor week 26 Jul 2026 Financial statements through 31 Mar 2026 Field coverage 82% Model confidence 78%

Relative factor standing

Higher display scores are better. Each score is converted from the underlying universe rank, where rank 1 is best.

Overall factor strength57/100Blend of value, momentum, and quality. Underlying universe rank 44; rank 1 is best.
Value52/100Relative valuation strength. Underlying universe rank 49; rank 1 is best.
Quality51/100Profitability and accounting quality. Underlying universe rank 50; rank 1 is best.
Momentum53/100Medium-term price momentum. Underlying universe rank 48; rank 1 is best.
Growth53/100Revenue and earnings growth. Underlying universe rank 48; rank 1 is best.
How to read this

Quality and valuation are separate questions

A strong company can still carry a demanding valuation. This report shows profitability, growth, balance-sheet strength, and the price paid for those characteristics separately.

Valuation

How much investors are paying for earnings, sales, and cash flow.

P/E
-
Price divided by trailing earnings.
Price / sales
0.0x
Market value relative to trailing revenue.
EV / EBITDA
-
Enterprise value relative to operating cash earnings.
Free-cash-flow yield
-205.1%
Free cash flow as a share of enterprise value.

Business quality

Margins and the return generated on invested capital.

Gross margin
0.2%
Gross profit retained from each unit of revenue.
Operating margin
-1.5%
Operating profit retained from revenue.
Free-cash-flow margin
-1.4%
Free cash flow generated from revenue.
Return on invested capital
-341.8%
Operating return generated on invested capital.

Growth and financial strength

Recent business growth and accounting strength.

Revenue growth
-
Latest one-year revenue growth.
EPS growth
-
Latest one-year earnings-per-share growth.
Free-cash-flow growth
-
Latest one-year free-cash-flow growth.
Piotroski F-score
5/9
Nine-point accounting-strength checklist.

Shareholder return and balance sheet

Cash returned to owners and financial leverage.

Dividend yield
-
Cash dividends relative to market value.
Buyback yield
-43.8%
Net share repurchases relative to market value.
Shareholder yield
-43.8%
Dividend yield plus net buyback yield.
Net debt / EBITDA
0.5x
Balance-sheet debt relative to operating cash earnings.
05 · Ownership, options, and sentiment

What other market participants are doing

Options, insider transactions, market sentiment, and activity-pressure signals can confirm or challenge the price story. None should be used alone.

Insider activity20 / 0

20 acquisitions and 0 disposals in the latest 180-day insider tape.

Acquisitions / disposals over the latest 180 days. Insider activity is context, not a stand-alone signal.
News sentiment55/100

Weighted news tone is neutral across 43 relevant articles.

16 positive · 23 neutral · 4 negative
Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal
06 · Catalysts and risk

What can move the shares—and how volatile the path has been

Event timing, options-implied movement, drawdown, and weekly return distribution frame the risk around the current setup.

Next earnings52dNext report is scheduled for 23 Sep 2026; event risk rises as the date approaches.
Options expected move-Nearest-chain priced movement where available.
52-week drawdown-41.2%Distance below the 52-week high.
13-week volatility46.0%Standard deviation of weekly returns.

Weekly gains and losses

Latest 26 completed weeks

Each bar is one week. Gains rise above the zero line; losses fall below it. Taller bars mean a larger weekly move.

Weeks higher11 of 2615 weeks finished lower.
Best week+168.7%Week of 22 May.
Worst week-19.8%Week of 27 Mar.
Latest week-14.0%Week of 31 Jul.

Shape of recent returns

Strong gains7
Modest gains4
Flat weeks0
Modest losses5
Sharp losses10
Recent vol46.0%13-week weekly-return volatility.
Base vol25.1%52-week weekly-return volatility.
Up/down split21/30Count of positive and negative weeks in the 52-week window.
Average skew13.5% / -8.0%Average positive week versus average negative week.
07 · Sector and peer context

Is this stock leading—or simply moving with its group?

Sector and industry breadth distinguish company-specific strength from a broad group move.

08 · Evidence and weekly data

The underlying research record

Every top-level statement above should be traceable to a stored market, fundamental, event, or positioning observation.

Weekly tape31/100

Trend, activity pressure, participation, and risk combine to a 31/100 tape read.

 Indicator analysis57/100

Latest 12-week confirmation: trend 6/12, activity pressure 12/12, relative leadership 1/12.

Activity pressure 0.74; No reversal markers Next-Week ExpectancyNegative 43.60%

Next-week expectancy is negative with a 43.60% historical one-week setup read.

Adds short-term historical context without overriding trend, activity, or relative leadership. Factors52/100

O'Shaughnessy factor stack blends value, quality, momentum, and confidence.

Buyback Yield rank 96 Patient CapitalQuiet

Activity-pressure buy-signal evidence highlights potential institutional accumulation windows.

No recent buy signal Sentiment55/100

Weighted news tone is neutral across 43 relevant articles.

InMed Pharmaceuticals Inc (INM) Financial Health: Profitability & Balance Sheet Analysis Insiders20 / 0

20 acquisitions and 0 disposals in the latest 180-day insider tape.

 Earnings52d

Next report is scheduled for 23 Sep 2026; event risk rises as the date approaches.
WeekCloseReturnTrend LineFair ValuePressureLeadershipVolumeTrend
31 Jul 20261.47 USD-14.0%1.12 USD4.61 USD0.98-6.131.2MOn
24 Jul 20261.71 USD12.5%1.10 USD4.73 USD1.097.7953.8MOn
17 Jul 20261.52 USD-7.3%1.09 USD4.86 USD1.02-7.39150.7KOn
10 Jul 20261.64 USD5.1%1.08 USD4.99 USD1.07-6.21243.0KOn
3 Jul 20261.56 USD1.3%1.07 USD5.10 USD1.10-11.10177.2KOn
26 Jun 20261.54 USD3.4%1.07 USD5.21 USD1.16-13.55174.6KOn
19 Jun 20261.49 USD-1.3%1.06 USD5.32 USD1.23-22.49108.5KOff
12 Jun 20261.51 USD-4.4%1.05 USD5.43 USD1.39-20.95327.8KOff
5 Jun 20261.58 USD0.6%1.06 USD5.58 USD1.20-17.02744.4KOff
29 May 20261.57 USD-8.7%1.06 USD5.74 USD0.89-23.01906.4KOff
22 May 20261.72 USD168.7%1.07 USD5.89 USD0.62-14.8198.1MOff
15 May 20260.64 USD-1.5%1.08 USD6.04 USD0.30-68.5694.8KOff
8 May 20260.65 USD-9.0%1.13 USD6.21 USD0.03-69.1783.6KOff
1 May 20260.71 USD-7.4%1.18 USD6.36 USD-0.04-65.13112.3KOff
How to use this report

This is a completed-week research summary. It explains the available evidence and its conflicts; it does not predict a guaranteed outcome or replace your own risk assessment. Fundamental figures may refer to an earlier financial reporting period, which is shown above.